Yanping Sun1, Shakti Ramkissoon2, Matthew A. Theisen2, Amy S. Freund3, Kristen L. Jones1, Marika Hayashi2, Juan Wang1, Keith Ligon2, Andrew L. Kung1, 4
1Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, MA, United States; 2Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 3Bruker BioSpin Corp., Billerica; 4 Pediatric Oncology, Childrens Hospital, Boston
Mutations in isocitrate dehydrogenase (IDH1/2) and excessive production of the 2-hydroxyglutarate (2HG) have been found in low grade gliomas and secondary glioblastomas (GBMs). In this study, we developed an intracranial xenograft GBM model harboring the IDH1-R132H mutation. MRI showed that T1 and T2 in tumor were higher, while tumor perfusion was lower, than normal tissue. 1D and 2D MRS demonstrated the presence of 2HG in IDH tumor but absent in control tumor. The tumor was characterized as a densely cellular glial neoplasm composed of large pleomorphic cells, which were positive by immunohistochemistry for the mutant form of IDH1